WO2023091608A3 - Methods for treating anti-cancer drug-related skin rashes using benralizumab - Google Patents

Methods for treating anti-cancer drug-related skin rashes using benralizumab Download PDF

Info

Publication number
WO2023091608A3
WO2023091608A3 PCT/US2022/050315 US2022050315W WO2023091608A3 WO 2023091608 A3 WO2023091608 A3 WO 2023091608A3 US 2022050315 W US2022050315 W US 2022050315W WO 2023091608 A3 WO2023091608 A3 WO 2023091608A3
Authority
WO
WIPO (PCT)
Prior art keywords
benralizumab
methods
cancer drug
related skin
skin rashes
Prior art date
Application number
PCT/US2022/050315
Other languages
French (fr)
Other versions
WO2023091608A2 (en
Inventor
Mario E. LACOUTURE
Original Assignee
Memorial Sloan-Kettering Cancer Center
Memorial Hospital For Cancer And Allied Diseases
Sloan-Kettering Institute For Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan-Kettering Cancer Center, Memorial Hospital For Cancer And Allied Diseases, Sloan-Kettering Institute For Cancer Research filed Critical Memorial Sloan-Kettering Cancer Center
Publication of WO2023091608A2 publication Critical patent/WO2023091608A2/en
Publication of WO2023091608A3 publication Critical patent/WO2023091608A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

The present disclosure relates generally to compositions comprising benralizumab, reslizumab, or mepolizumab and methods for using the same to treat or prevent anti-cancer drug-related skin rashes.
PCT/US2022/050315 2021-11-18 2022-11-17 Methods for treating anti-cancer drug-related skin rashes using benralizumab WO2023091608A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163280707P 2021-11-18 2021-11-18
US63/280,707 2021-11-18
US202263331509P 2022-04-15 2022-04-15
US63/331,509 2022-04-15

Publications (2)

Publication Number Publication Date
WO2023091608A2 WO2023091608A2 (en) 2023-05-25
WO2023091608A3 true WO2023091608A3 (en) 2023-08-24

Family

ID=86397713

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/050315 WO2023091608A2 (en) 2021-11-18 2022-11-17 Methods for treating anti-cancer drug-related skin rashes using benralizumab

Country Status (1)

Country Link
WO (1) WO2023091608A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050226867A1 (en) * 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
US20110196353A1 (en) * 2010-02-05 2011-08-11 Deland Maitland M LED Treatment of Dermatologic Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors
US20160158205A1 (en) * 2013-07-12 2016-06-09 Knopp Biosciences Llc Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils
US20200040073A1 (en) * 2007-04-30 2020-02-06 Glaxosmithkline Llc Methods for administering anti-il-5 antibodies
US20200040088A1 (en) * 2017-01-24 2020-02-06 Kyowa Kirin Co., Ltd. Therapeutic or prophylactic agent and treatment or prevention method for radiation damage

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050226867A1 (en) * 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
US20200040073A1 (en) * 2007-04-30 2020-02-06 Glaxosmithkline Llc Methods for administering anti-il-5 antibodies
US20110196353A1 (en) * 2010-02-05 2011-08-11 Deland Maitland M LED Treatment of Dermatologic Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors
US20160158205A1 (en) * 2013-07-12 2016-06-09 Knopp Biosciences Llc Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils
US20200040088A1 (en) * 2017-01-24 2020-02-06 Kyowa Kirin Co., Ltd. Therapeutic or prophylactic agent and treatment or prevention method for radiation damage

Also Published As

Publication number Publication date
WO2023091608A2 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
MX2019011431A (en) Pd-1/pd-l1 inhibitors.
MX2022007515A (en) Sos1 inhibitors.
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
MX2022005216A (en) Pyridazinones as parp7 inhibitors.
MX2019008701A (en) Combination therapy involving diaryl macrocyclic compounds.
UA89226C2 (en) Imidazole compounds
WO2019090347A8 (en) Adenosine pathway inhibitors for cancer treatment
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
AU2018271862A1 (en) Combination therapy
CL2021002212A1 (en) Treatment of kidney injury
MX2023004156A (en) Combination therapy for treating cancer.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2022002337A (en) Modified tff2 polypeptides.
WO2018208954A3 (en) Peptidomimetic macrocycles and uses thereof
MX2022006853A (en) Macrocycles for use in treating disease.
WO2019023315A3 (en) Rac inhibitors
WO2022218941A3 (en) Compositions and methods for inhibiting ketohexokinase (khk)
MX2021004709A (en) Method and medicament for treating cancer unresponsive to pd-1/pd-l1 signaling inhibitor.
WO2019075216A8 (en) Plectin-1 binding antibodies and uses thereof
WO2023091608A3 (en) Methods for treating anti-cancer drug-related skin rashes using benralizumab
JOP20210009A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2023004881A (en) Pde9 inhibitors for treating cardiac failure.
MX2023005171A (en) Compositions and methods for treating solid cancer.
MX2022008632A (en) Ccr5 binding agent for treatment of ccr5 positive metastatic cancer.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22896493

Country of ref document: EP

Kind code of ref document: A2